DiGeorge Syndrome
16
2
3
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
2 terminated out of 16 trials
81.8%
-4.7% vs benchmark
6%
1 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (16)
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
Immune Disorder HSCT Protocol
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Thymus Transplantation Safety-Efficacy
Parathyroid and Thymus Transplantation in DiGeorge #931
Thymus Transplantation With Immunosuppression
Thymus Transplantation in DiGeorge Syndrome #668
Thymus Transplantation Dose in DiGeorge #932
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Whole Blood Specimen Collection From Pregnant Subjects
Effects of PTH Replacement on Bone in Hypoparathyroidism
Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
Infection in DiGeorge Following CHD Surgery
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome